Neuland Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 15, 2025, recommended Final Dividend of Rs. 12 per equity share.

Revenue DeclineEbitda Margin CompressionExceptional ItemResults View source PDF Explain this filing

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-7.2%Reaction day

₹11899.00

prior close

₹11050.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.5%-8.7% vs market

Pharmaceuticals peers, median of 150sector+0.2%-7.4% vs sector

On the reaction day the stock moved 8.7 pts less than Nifty Smallcap 250 and 7.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+0.9

15m

+2.5

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-7.2+1.5-8.7+0.2-7.4

Next day

-5.5+2.2-7.7+1.1-6.6

-6.2+1.3-7.5+0.2-6.4

-6.1+1.7-7.8+1.0-7.1

-6.2+1.7-7.9+1.2-7.4

-6.6+2.3-8.9+0.7-7.4

-6.6+3.0-9.6+1.4-8.0

15d

+8.4+7.0+1.4+0.6+7.8

+7.4+7.0+0.4+2.1+5.4

+20.5+11.3+9.2+3.8+16.7

+13.5+4.5+9.0-1.0+14.4

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Neuland Laboratories' board met on May 15, 2025 and approved audited standalone and consolidated financial results for FY25 with an unmodified (clean) opinion from statutory auditor MSKA & Associates. Consolidated revenue from operations fell to Rs. 147,683.73 lakhs from Rs. 155,858.05 lakhs in FY24, a decline of about 5.3%. Profit after tax dropped to Rs. 26,010.81 lakhs from Rs. 30,007.89 lakhs, with EPS at Rs. 202.74 vs Rs. 233.89. The decline in core profitability was partly offset by an exceptional gain of Rs. 7,640.36 lakhs from transferring an investment property in Nanakramguda, Hyderabad through a perpetual lease. The board recommended a final dividend of Rs. 12 per share (120% on face value of Rs. 10), subject to shareholder approval at the 41st AGM on July 30, 2025, with July 18, 2025 as the record date. Additionally, Mr. Davuluri Saharsh Rao was re-appointed as Vice Chairman & Managing Director for five years from June 1, 2025, and P.S. Rao & Associates were appointed as Secretarial Auditors for FY26–FY30.

Likely market impact

The weak FY25 operating performance (lower revenue, lower core margins, and a sharp PAT decline) may pressure the stock in the near term, though the final dividend offers some support to income-focused investors. The exceptional property gain flatters headline profit and operating cash flow remains healthy at Rs. 31,738 lakhs, but investors should focus on the underlying core business trend which shows clear margin compression.